Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that …